Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 79

1.

Nuclear trafficking of the HIV-1 pre-integration complex depends on the ADAM10 intracellular domain.

Endsley MA, Somasunderam AD, Li G, Oezguen N, Thiviyanathan V, Murray JL, Rubin DH, Hodge TW, O'Brien WA, Lewis B, Ferguson MR.

Virology. 2014 Apr;454-455:60-6. doi: 10.1016/j.virol.2014.02.006. Epub 2014 Feb 22.

2.

The clinical impact of continuing to prescribe antiretroviral therapy in patients with advanced AIDS who manifest no virologic or immunologic benefit.

Wohl DA, Kendall MA, Feinberg J, Alston-Smith B, Owens S, Chafey S, Marco M, Maxwell S, Benson C, Keiser P, van der Horst C, Jacobson MA; A5030 Study Team.

PLoS One. 2013 Nov 15;8(11):e78676. doi: 10.1371/journal.pone.0078676. eCollection 2013.

3.

Outcomes by sex following treatment initiation with atazanavir plus ritonavir or efavirenz with abacavir/lamivudine or tenofovir/emtricitabine.

Smith KY, Tierney C, Mollan K, Venuto CS, Budhathoki C, Ma Q, Morse GD, Sax P, Katzenstein D, Godfrey C, Fischl M, Daar ES, Collier AC; AIDS Clinical Trials Group 5202 Study Team.

Clin Infect Dis. 2014 Feb;58(4):555-63. doi: 10.1093/cid/cit747. Epub 2013 Nov 18.

4.

Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settings.

Campbell TB, Smeaton LM, Kumarasamy N, Flanigan T, Klingman KL, Firnhaber C, Grinsztejn B, Hosseinipour MC, Kumwenda J, Lalloo U, Riviere C, Sanchez J, Melo M, Supparatpinyo K, Tripathy S, Martinez AI, Nair A, Walawander A, Moran L, Chen Y, Snowden W, Rooney JF, Uy J, Schooley RT, De Gruttola V, Hakim JG; PEARLS study team of the ACTG.

PLoS Med. 2012;9(8):e1001290. Epub 2012 Aug 14.

5.

Identification of cellular proteins required for replication of human immunodeficiency virus type 1.

Dziuba N, Ferguson MR, O'Brien WA, Sanchez A, Prussia AJ, McDonald NJ, Friedrich BM, Li G, Shaw MW, Sheng J, Hodge TW, Rubin DH, Murray JL.

AIDS Res Hum Retroviruses. 2012 Oct;28(10):1329-39. Epub 2012 Apr 20.

6.

Inhibition of influenza A virus replication by antagonism of a PI3K-AKT-mTOR pathway member identified by gene-trap insertional mutagenesis.

Murray JL, McDonald NJ, Sheng J, Shaw MW, Hodge TW, Rubin DH, O'Brien WA, Smee DF.

Antivir Chem Chemother. 2012 May 14;22(5):205-15. doi: 10.3851/IMP2080.

PMID:
22374988
7.

Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results.

Sax PE, Tierney C, Collier AC, Daar ES, Mollan K, Budhathoki C, Godfrey C, Jahed NC, Myers L, Katzenstein D, Farajallah A, Rooney JF, Ha B, Woodward WC, Feinberg J, Tashima K, Murphy RL, Fischl MA; AIDS Clinical Trials Group Study A5202 Team.

J Infect Dis. 2011 Oct 15;204(8):1191-201. doi: 10.1093/infdis/jir505.

8.

A functional role for ADAM10 in human immunodeficiency virus type-1 replication.

Friedrich BM, Murray JL, Li G, Sheng J, Hodge TW, Rubin DH, O'Brien WA, Ferguson MR.

Retrovirology. 2011 May 11;8:32. doi: 10.1186/1742-4690-8-32.

9.

Failure of initial therapy with two nucleosides and efavirenz is not associated with early emergence of mutations in the C-terminus of HIV-1 reverse transcriptase.

Brehm JH, Lalama CM, Hughes MD, Haubrich R, Riddler SA, Sluis-Cremer N, Mellors JW; AIDS Clinical Trials Group Study A5142 Protocol Team.

J Acquir Immune Defic Syndr. 2011 Apr;56(4):344-8. doi: 10.1097/QAI.0b013e31820cf029.

10.

Long-term increase in CD4+ T-cell counts during combination antiretroviral therapy for HIV-1 infection.

Lok JJ, Bosch RJ, Benson CA, Collier AC, Robbins GK, Shafer RW, Hughes MD; ALLRT team.

AIDS. 2010 Jul 31;24(12):1867-76. doi: 10.1097/QAD.0b013e32833adbcf.

11.

Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort.

Robertson KR, Su Z, Margolis DM, Krambrink A, Havlir DV, Evans S, Skiest DJ; A5170 Study Team.

Neurology. 2010 Apr 20;74(16):1260-6. doi: 10.1212/WNL.0b013e3181d9ed09. Epub 2010 Mar 17.

12.

Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy.

Sax PE, Tierney C, Collier AC, Fischl MA, Mollan K, Peeples L, Godfrey C, Jahed NC, Myers L, Katzenstein D, Farajallah A, Rooney JF, Ha B, Woodward WC, Koletar SL, Johnson VA, Geiseler PJ, Daar ES; AIDS Clinical Trials Group Study A5202 Team.

N Engl J Med. 2009 Dec 3;361(23):2230-40. doi: 10.1056/NEJMoa0906768. Epub 2009 Dec 1.

13.

Low rate of CMV end-organ disease in HIV-infected patients despite low CD4+ cell counts and CMV viremia: results of ACTG protocol A5030.

Wohl DA, Kendall MA, Andersen J, Crumpacker C, Spector SA, Feinberg J, Alston-Smith B, Owens S, Chafey S, Marco M, Maxwell S, Lurain N, Jabs D, Benson C, Keiser P, Jacobson MA; A5030 Study Team.

HIV Clin Trials. 2009 May-Jun;10(3):143-52. doi: 10.1310/hct1003-143.

14.

Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment.

Haubrich RH, Riddler SA, DiRienzo AG, Komarow L, Powderly WG, Klingman K, Garren KW, Butcher DL, Rooney JF, Haas DW, Mellors JW, Havlir DV; AIDS Clinical Trials Group (ACTG) A5142 Study Team.

AIDS. 2009 Jun 1;23(9):1109-18. doi: 10.1097/QAD.0b013e32832b4377.

15.

Improvement in lipid profiles over 6 years of follow-up in adults with AIDS and immune reconstitution.

Williams P, Wu J, Cohn S, Koletar S, McCutchan J, Murphy R, Currier J; AIDS Clinical Trials Group 362 Study Team.

HIV Med. 2009 May;10(5):290-301. doi: 10.1111/j.1468-1293.2008.00685.x. Epub 2009 Feb 8.

16.

Impact of human immunodeficiency virus type 1 reverse transcriptase inhibitor drug resistance mutation interactions on phenotypic susceptibility.

Trivedi V, Von Lindern J, Montes-Walters M, Rojo DR, Shell EJ, Parkin N, O'Brien WA, Ferguson MR.

AIDS Res Hum Retroviruses. 2008 Oct;24(10):1291-300. doi: 10.1089/aid.2007.0244.

17.

A critical role for CD63 in HIV replication and infection of macrophages and cell lines.

Chen H, Dziuba N, Friedrich B, von Lindern J, Murray JL, Rojo DR, Hodge TW, O'Brien WA, Ferguson MR.

Virology. 2008 Sep 30;379(2):191-6. doi: 10.1016/j.virol.2008.06.029. Epub 2008 Aug 5.

18.

Class-sparing regimens for initial treatment of HIV-1 infection.

Riddler SA, Haubrich R, DiRienzo AG, Peeples L, Powderly WG, Klingman KL, Garren KW, George T, Rooney JF, Brizz B, Lalloo UG, Murphy RL, Swindells S, Havlir D, Mellors JW; AIDS Clinical Trials Group Study A5142 Team.

N Engl J Med. 2008 May 15;358(20):2095-106. doi: 10.1056/NEJMoa074609.

19.

Randomized study of dual versus single ritonavir-enhanced protease inhibitors for protease inhibitor-experienced patients with HIV.

Collier AC, Tierney C, Downey GF, Eshleman SH, Kashuba A, Klingman K, Vergis EN, Pakes GE, Rooney JF, Rinehart A, Mellors JW; AIDS Clinical Trials Group Protocol A5143 Team.

HIV Clin Trials. 2008 Mar-Apr;9(2):91-102. doi: 10.1310/hct0902-91.

PMID:
18474494
20.

Evolution of HIV resistance mutations in patients maintained on a stable treatment regimen after virologic failure.

Goetz MB, Ferguson MR, Han X, McMillan G, St Clair M, Pappa KA, McClernon DR, O'Brien WA.

J Acquir Immune Defic Syndr. 2006 Dec 15;43(5):541-9.

Supplemental Content

Loading ...
Support Center